Abstract:

Objective To evaluate the effects of lysine inositol vitamin B12 oral solution in conjunction with recombinant human growth hormone （rhGH） on bone mineral density （BMD） and insulin-like growth factor-1 （IGF-1） levels in children with idiopathic short stature. Methods A total of 92 children diagnosed with idiopathic dwarfism at the Affiliated Hospital of Chengde Medical College between August 2021 and March 2024 were recruited and randomly divided into two groups using a random number table method. The rhGH group received recombinant human growth hormone （rhGH） at a dose of 0.15 U/kg/day， while the comprehensive treatment group received lysyl myo-inositol and vitamin B₁₂ oral solution in addition to rhGH. Growth and development indices， IGF-1 levels， bone metabolism markers， serum calcium， serum phosphorus， and vitamin D levels were compared between the two groups. Additionally， adverse reactions were monitored and recorded for both groups. Results Comparison of growth and development indicators in children with idiopathic dwarfism before treatment between the two groups showed no significant difference （P > 0.05）. After 12 months of treatment， both groups exhibited increased growth rates， height standard deviation scores， and body mass indices compared to pre-treatment levels， with the combined group showing significantly higher values than the rhGH group （P < 0.05）. Similarly， there was no significant difference in IGF-1 levels between the two groups before treatment （P > 0.05）. However， at 6 and 12 months post-treatment， IGF-1 levels were significantly higher in both groups compared to baseline， with the combined group demonstrating significantly greater increases than the rhGH group （P < 0.05）. Regarding bone metabolism parameters， blood calcium， blood phosphorus， and vitamin D levels， no significant differences were observed between the two groups prior to treatment （P > 0.05）. At 12 months post-treatment， bone mineral density， bone alkaline phosphatase （BAP）， typeⅠprocollagen amino-terminal propeptide （PINP）， blood calcium， blood phosphorus， and vitamin D levels were significantly higher in both groups compared to pre-treatment levels， with the combined group showing significantly greater improvements than the rhGH group （P < 0.05）. Cumulative adverse effects did not differ significantly between the integrated group and the rhGH group （P > 0.05）. Conclusion The combination of lysine， inositol， vitamin B₁₂ oral solution and rhGH enhances bone metabolism and promotes growth in children with idiopathic short stature.

Key words: lysine inositol vitamin B₁₂, recombinant human growth hormone, idiopathic dwarfism, bone metabolism, growth and development